CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2018--
announced today that its chief medical officer, Aoife Brennan, M.B.,
B.Ch., and chief financial officer, Todd Shegog will present a corporate
update at the Leerink Partners 7th Annual Global Healthcare Conference
at 3:00 p.m. ET, on Thursday, February 15, 2018, in New York City.
A live webcast of the presentation can be accessed under “Presentations”
in the Investors & Media section of the Company’s website at www.synlogictx.com.
An archived webcast recording will be available on the Synlogic website
for approximately 30 days after the event.
Synlogic is pioneering the development of a novel class of living
treatments, Synthetic Biotic medicines, based on its proprietary drug
development platform. Synlogic’s initial pipeline includes Synthetic
Biotic medicines for the treatment of rare genetic diseases, such as
Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the
company is leveraging the broad potential of its platform to create
Synthetic Biotic medicines for the treatment of more common diseases,
including liver disease, inflammatory and immune disorders, and cancer.
Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based
treatments for inflammatory bowel disease (IBD). For more information,
please visit www.synlogictx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180208006381/en/
Courtney Heath, 617-872-2462
Elizabeth Wolffe, Ph.D., 617-207-5509